Last reviewed · How we verify
GSK2190915 100
At a glance
| Generic name | GSK2190915 100 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- GSK2190915 Moderate to Severe Asthma Study (PHASE2)
- A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise (PHASE2)
- A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A (PHASE1)
- A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin (PHASE1)
- Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2190915 100 CI brief — competitive landscape report
- GSK2190915 100 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI